Solu
Latest round
- Seed
Last raised
- Jun 2023
Total raised
- $1.1M
Investors
- 2
About Solu
Founded in 2022 by Sam Sihvonen (CEO), Timo Moilanen, and Kerkko Visuri, and based in Delaware, US, Solu Healthcare, Inc, doing business as Solu, operates as a biotechnology company that focuses on the research and development of antibiotic resistance prevention and detection drugs. The firm employs genome sequencing methodology building a bacterial DNA library to study pathogens and analyze, monitor, and control antibiotic-resistant bacteria. The firm also develops software to understand, detect, and prevent the spread of antibiotic resistance and develop new treatment methods against resistant bacteria.
Who invested in Solu
2 investors across 1 round
See all investors in Solu
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jun 15, 2023
Amount
$1.1M
Investors
Questions about Solu
Who invested in Solu?
Solu has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Solu raised?
Solu has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Solu last raise money?
Solu's most recent round on record is a Seed, in Jun 2023.
What does Solu do?
Founded in 2022 by Sam Sihvonen (CEO), Timo Moilanen, and Kerkko Visuri, and based in Delaware, US, Solu Healthcare, Inc, doing business as Solu, operates as a biotechnology company that focuses on the research and development of antibiotic resistance prevention and detection drugs.
Where is Solu headquartered?
Solu is headquartered in US.
Which VCs invest in companies like Solu?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Solu's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Solu? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.